Free Trial

This company has been marked as potentially delisted and may not be actively trading.

NASDAQ:FIXX

Homology Medicines (FIXX) Stock Price, News & Analysis

Homology Medicines logo

About Homology Medicines Stock (NASDAQ:FIXX)

Advanced Chart

Key Stats

Today's Range
N/A
50-Day Range
$0.33
$16.82
52-Week Range
N/A
Volume
22,300 shs
Average Volume
390,307 shs
Market Capitalization
$978.01 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Homology Medicines Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
13th Percentile Overall Score

FIXX MarketRank™: 

Homology Medicines scored higher than 13% of companies evaluated by MarketBeat, and ranked 886th out of 938 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    There is not enough analysis data for Homology Medicines.

  • Earnings Growth

    Earnings for Homology Medicines are expected to grow in the coming year, from ($0.75) to ($0.70) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Homology Medicines is -8.58, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Homology Medicines is -8.58, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Short Interest

    There is no current short interest data available for FIXX.
  • Dividend Yield

    Homology Medicines does not currently pay a dividend.

  • Dividend Growth

    Homology Medicines does not have a long track record of dividend growth.

  • Short Interest

    There is no current short interest data available for FIXX.
  • Search Interest

    1 people have searched for FIXX on MarketBeat in the last 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Homology Medicines insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    16.10% of the stock of Homology Medicines is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    Only 31.32% of the stock of Homology Medicines is held by institutions.

  • Read more about Homology Medicines' insider trading history.
Receive FIXX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Homology Medicines and its competitors with MarketBeat's FREE daily newsletter.

FIXX Stock News Headlines

Forget Nvidia, This “Ghost Town” Company Holds the Key to the AI Boom
Cold War Discovery Could Unlock $100 Trillion in Wealth Jeff recently traveled to an American ghost town to investigate this crazy Cold War story… Because it could hold the key to the entire $100 trillion AI boom. It involves an American ghost town with just 30 people… And a new twist to the AI boom that could make a lot of people rich.
FIXX Homology Medicines, Inc.
Homology Medicines Inc (FIXX)
See More Headlines

FIXX Stock Analysis - Frequently Asked Questions

Homology Medicines, Inc. (NASDAQ:FIXX) issued its earnings results on Monday, November, 15th. The company reported ($0.27) earnings per share for the quarter, topping analysts' consensus estimates of ($0.30) by $0.03. The firm earned $1.68 million during the quarter, compared to analyst estimates of $0.63 million. Homology Medicines had a negative net margin of 4,779.31% and a negative trailing twelve-month return on equity of 102.52%.

Homology Medicines's stock split before market open on Wednesday, March 20th 2024.The 2-1 split was announced on Wednesday, March 20th 2024. The newly issued shares were issued to shareholders after the market closes on Wednesday, March 20th 2024. An investor that had 100 shares of stock prior to the split would have 200 shares after the split.

Homology Medicines (FIXX) raised $100 million in an initial public offering on Wednesday, March 28th 2018. The company issued 6,700,000 shares at $14.00-$16.00 per share. BofA Merrill Lynch, Cowen and Evercore ISI served as the underwriters for the IPO and BTIG was co-manager.

Based on aggregate information from My MarketBeat watchlists, some other companies that Homology Medicines investors own include Editas Medicine (EDIT), NVIDIA (NVDA), Enovix (ENVX), Luminar Technologies (LAZR), Advanced Micro Devices (AMD), Ginkgo Bioworks (DNA) and Tesla (TSLA).

Company Calendar

Last Earnings
11/15/2021
Today
7/13/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:FIXX
CIK
1661998
Fax
N/A
Employees
7
Year Founded
2015

Profitability

EPS (Trailing Twelve Months)
($1.96)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$112.96 million
Net Margins
-4,779.31%
Pretax Margin
-7,532.87%
Return on Equity
-102.52%
Return on Assets
-74.91%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
7.25
Quick Ratio
7.25

Sales & Book Value

Annual Sales
$1.16 million
Price / Sales
0.00
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$1.26 per share
Price / Book
N/A

Miscellaneous

Outstanding Shares
58,130,000
Free Float
48,774,000
Market Cap
$978.01 million
Optionable
Optionable
Beta
-0.10

Social Links

The Best High-Yield Dividend Stocks for 2025 Cover

Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

This page (NASDAQ:FIXX) was last updated on 7/13/2025 by MarketBeat.com Staff
From Our Partners